CD274 and non-small cell lung carcinoma: In a phase II study (NCT02608268), sabatolimab in combination with spartalizumab (anti-PD-1 antibody) was used in patients with melanoma, renal cell carcinoma, or NSCLC who had progressive disease at or after therapy with anti-PD-1 or anti-PD-L1 antibodies.